Lille (France), Boston (Massachusetts, United States), November 3, 2014 – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces two events and a GFT505 poster presentation during the annual meeting of the American Association for the Study of Liver Disease, “The Liver Meeting 2014,” held in Boston, Massachusetts from November 7-11, 2014. In addition to the poster presentation, GENFIT will detail to the key opinion leaders its strategy regarding the NASH market in several symposia. “The Liver Meeting” organized by the AASLD is an annual meeting of the scientific and medical community specialized in hepatology. This international conference brings together more than 10,000 scientists, gastroenterologists and hepatologists and will provide an update on the latest scientific and medical advances to improve the management of patients and their treatment.
Several sessions will be held on the epidemiology, the pathophysiology, the diagnostic tools, the support for patients and future treatments of NASH. As such, GENFIT will present the latest results of GFT505, its drug candidate, as well as its strategy to combat this pathology.
GFT505 Poster Presentation at AASLD
Sunday, November 9th in Poster Hall C
“GFT505 reverses NASH pathology, obesity and insulin resistance in the foz/foz model” (Poster 1155). Isabelle A. Leclercq, Vanessa Legry, Benoît Noel, Rémy Hanf, Dean W. Hum, Robert Walczak.
In addtion, GENFIT will host two specific events:
- On Sunday, November 9, an ‘investors and analyst’ meeting in which opinion leaders and GENFIT’s management will present their vision on NASH (scientific, medical and epidemiological issues) as well as the potential of GFT505 as treatment of this liver disease.
- GENFIT will also host a private meeting bringing together experts and investigators of the ongoing GFT505 Phase 2b study for an update on the progress of this study on NASH, and discuss the topics which were addressed during the meeting with the FDA held mid-October in preparation of the Phase 3 clinical trials.
Jean François Mouney, Chairman and Chief Executive Officer of GENFIT, declared: “The AASLD program clearly shows that the global epidemic of NASH has become a major concern for the scientific and medical community. Research efforts to try to address public health issues raised by NASH are increasingly important. GENFIT is recognized as a major player in the field as the Company is working to provide innovative therapeutic and diagnostic solutions to patients, and their doctors, suffering from the lack of treatments.”
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT’s R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT’s lead proprietary compound, GFT505, that is completing a Phase 2b study in NASH. With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed in compartment B of Euronext’s regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com
Disclaimer:
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on GENFIT’s website (www.genfit.com). This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.
Help employers find you! Check out all the jobs and post your resume.
